XML 89 R58.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Disclosures - Schedule of Significant Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Operating expenses:                
Non-cash stock compensation             $ 7,555 $ 6,542
Total operating expenses $ 25,993     $ 25,726     79,901 72,421
Loss from operations (25,993)     (25,726)     (79,901) (72,421)
Interest income 419     776     843 2,961
Change in fair value of the tranche rights 0     0     0 (4,796)
Other income (expense) (5)     582     1,186 (1,076)
Net loss (25,579) $ (26,820) $ (25,473) (24,368) $ (21,380) $ (29,584) (77,872) (75,332)
Reportable Segment                
Operating expenses:                
Clinical product candidates 15,285     17,338     50,776 47,220
Pre-clinical product candidates 480     359     825 760
Non-cash stock compensation 3,614     1,910     7,555 6,541
Depreciation expense 40     42     126 99
Professional fees and other segment expenses 2,450     2,428     8,090 7,567
Total operating expenses 25,993     25,726     79,901 72,421
Loss from operations (25,993)     (25,726)     (79,901) (72,421)
Interest income 419     776     843 2,961
Change in fair value of the tranche rights             0 (4,796)
Other income (expense) (5)     582     1,186 (1,076)
Net loss (25,579)     (24,368)     (77,872) (75,332)
Reportable Segment | Employee costs- research and development                
Operating expenses:                
Employee costs 2,463     2,074     7,224 5,955
Reportable Segment | Employee costs-general and administrative                
Operating expenses:                
Employee costs $ 1,661     $ 1,575     $ 5,305 $ 4,279